The elevated eEF2 K expression correlates with worse survival outcomes in specific breast cancer subtypes, and its silencing, as part of an HNP-based therapy, may offer an innovative approach for improving prognosis in TNBC patients Fig. 3. The gene discussed is EEF2K; the disease is breast carcinoma.